Please assess the completion status of the following clinical trial:

Trial Title: A Study in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients aged ≥ 40 years, who have signed an Informed Consent form prior to initiation of any study-related procedure or once applicable written informed consent obtained by legal representative.~2. Outpatients with a diagnosis of COPD and including:~   1. Smoking history of at least 10 pack years defined as \[(number of cigarettes smoked per day) x (number of years of smoking) / 20\], both current and ex-smokers are eligible.~  2. Use of bronchodilators in the previous 2 months to visit 1.~  3. Post-bronchodilator FEV1 \< 60% of the predicted normal value.~  4. Post-bronchodilator FEV1/FVC \< 0.7.~  5. A ≥ 5% response to a reversibility test.~  6. A Baseline Dyspnoea Index (BDI) focal score less or equal than 10 (to be met also at visit 2).~3. History of no more than one COPD exacerbation in the previous 12 months (without considering the last 2 months) to visit 1.~4. A cooperative attitude and ability to be trained to the proper use of pMDI and DPI (Accuhaler®, circular moulded plastic inhaler) inhalers.~Main Exclusion Criteria:~1. Clinically relevant respiratory disorders.~2. Current diagnosis of asthma or respiratory disorders other than COPD.~3. Clinically significant laboratory and ECG abnormalities indicating a significant or unstable concomitant disease which may impact the feasibility of the results of the study according to investigator's judgement.~4. Patients with COPD exacerbation in the 2 months prior to screening and during the study period.~5. Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia.~6. Patients treated with depot corticosteroids in the 2 months preceding the visit 1 and during the run-in period.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Foster® (Type: EXPERIMENTAL): Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg).
- Seretide® Accuhaler® (Type: ACTIVE_COMPARATOR): Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).

Based on this trial design, predict the completion outcome and termination type (if applicable).